Pfizer and Medivation have reported unsuccessful results from a Phase III trial of investigational drug Dimebon (latrepirdine) in patients with Huntington’s disease.
The results revealed that Dimebon did not achieve statistical significance for either of the co-primary endpoints: the Mini-Mental State Examination, which measures cognition; or the Clinician’s Interview-Based Impression of Change plus care-giver input, which measures global function.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Dimebon was generally well-tolerated in the double-blind, placebo-controlled study, which enrolled 403 patients with Huntington’s at 64 sites in North America, Europe and Australia.
Patients were randomised to receive either 20mg of Dimebon three times a day or a placebo, for six months.
Following the result, the companies have decided to discontinue development of Dimebon as a treatment for Huntington’s disease, including the ongoing open-label extension study.
The oral medication is also developed for the treatment of Alzheimer’s disease.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
